G1 THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
G1 THERAPEUTICS, INC. reported Share-based Payment Arrangement, Expense of $2.09 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2024-08-08
- G1 THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2024-06-30 was $2.09M, a 45.14% decline year-over-year.
- G1 THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2024-03-31 was $2.55M, a 33.63% decline year-over-year.
- G1 THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2023-12-31 was $3.21M, a 27.07% decline year-over-year.
- G1 THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2023-09-30 was $3.65M, a 23.62% decline year-over-year.
- G1 THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $14.51M, a 29.53% decline from fiscal 2022.
- G1 THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $20.59M, a 7.75% decline from fiscal 2021.
- G1 THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2021 was $22.32M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $2.09M 10-Q · filed 2024-08-08 | $4.64M 10-Q · filed 2024-08-08 | $7.84M derived: sum of 3 quarters · filed 2024-08-08 | $11.50M derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | $2.55M 10-Q · filed 2024-05-01 | $5.75M derived: sum of 2 quarters · filed 2024-05-01 | $9.41M derived: sum of 3 quarters · filed 2024-05-01 | $13.22M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $6.86M derived: sum of 2 quarters · filed 2024-02-28 | $10.67M derived: sum of 3 quarters · filed 2024-08-08 | $14.51M 10-K · filed 2024-02-28 |
| 2023-09-30 | $3.65M 10-Q · filed 2023-11-01 | $7.46M derived: sum of 2 quarters · filed 2024-08-08 | $11.30M 10-Q · filed 2023-11-01 | $15.70M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | $3.81M 10-Q · filed 2024-08-08 | $7.65M 10-Q · filed 2024-08-08 | $12.05M derived: sum of 3 quarters · filed 2024-08-08 | $16.83M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.84M 10-Q · filed 2024-05-01 | $8.24M derived: sum of 2 quarters · filed 2024-05-01 | $13.02M derived: sum of 3 quarters · filed 2024-05-01 | $18.66M derived: sum of 4 quarters · filed 2024-05-01 |
| 2022-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $9.19M derived: sum of 2 quarters · filed 2024-02-28 | $14.82M derived: sum of 3 quarters · filed 2024-02-28 | $20.59M 10-K · filed 2024-02-28 |
| 2022-09-30 | $4.79M 10-Q · filed 2023-11-01 | $10.42M derived: sum of 2 quarters · filed 2023-11-01 | $16.19M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $5.64M 10-Q · filed 2023-08-02 | $11.40M 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | $5.76M 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | $22.32M 10-K · filed 2024-02-28 | |||
| 2017-06-30 | $769.00K 10-Q · filed 2017-08-09 | $1.32M 10-Q · filed 2017-08-09 | ||
| 2016-06-30 | $318.00K 10-Q · filed 2017-08-09 | $539.00K 10-Q · filed 2017-08-09 |